Are you waiting 6, or even 12 months to fill your product? Symbiosis can help fill your product faster.
Learn how Symbiosis can help get your product to the next stage
Take a look at our latest vacancies or submit an open application
We have extensive experience in taking precious, complex drug products from manufacture to QP release.
Clinical and small scale commercial manufacturing of advanced therapeutics such as viral vectors for cell and gene therapies, oncolytic viruses and critical raw materials such as plasmids.
Extensive experience in delivering hundreds of projects allowing us to support your clinical trials.
Symbiosis can support with challenging manufacturing and handling requirements that need specialist knowledge and experience.
Overcome your development and manufacturing challenges with a partner that has the experience and capabilities to handle your highly potent ADC
Symbiosis has provided GMP manufacturing across a wide range of small molecule applications, including highly potent materials requiring specialist handling.
Rapid access to sterile fill-finish manufacturing slots
Symbiosis values time as much as you do. We offer rapid access to GMP aseptic fill-finish manufacturing slots and have world class expertise and experience across a full range of biologics, including ATMPs, mAbs and vaccines. We also specialise in the manufacture of small molecules.
Choose Symbiosis Pharmaceutical Services for your clinical or small-scale commercial manufacturing project and get your product to patients faster.
Contact us to find a manufacturing slot that fits with your project timescales.
Fill in your details to be added to our mailing list and receive our latest updates.
See our latest news, resources and upcoming events.
15th May 2023
In 2021 the investment in funding more than 1,200 clinical trials of personalised cell and gene therapies worldwide is an indicator of ...
4th May 2023
The biopharmaceutical industry is experiencing a paradigm shift in the treatment of complex diseases, particularly oncology, thanks to a surge ...
13th April 2023
Introduction With the global spend on medicines projected to increase to $1.29tn in 2027[i], contract manufacturing organisations (CMOs) are experiencing ...
20th March 2023
In this edition of the Symbiosis Meet the Team, we sit down with our newly appointed Business Development Manager, Linda ...
14th March 2023
The development of Antibody-Drug Conjugate (ADC) technologies has facilitated the enhanced targeting of cancer cells with reduced toxic side effects ...